Fisher Asset Management
IRD

Fisher Asset Management’s Opus Genetics IRD Stock Holding History

Fisher Asset Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-21
Closed -$9K – 572
2014
Q2 		$9K Buy
+21
New +$9.55K ﹤0.01% 553

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.33B AUM 19.79% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fisher Asset Management's IRD Position: Q3 2014 in Review

Fisher Asset Management sold out of Opus Genetics (IRD) in Q3 2014, closing a stake of 21 shares — an estimated $9K sold.

Fisher Asset Management first reported a position in IRD in Q2 2014 and held it in 1 quarter. The position peaked at $9K in Q2 2014. 31 funds tracked by Wall St. Rank hold IRD as of Q3 2014.

  • Fisher Asset Management reported no remaining Opus Genetics position as of Q3 2014 after selling out during the quarter.
  • Fisher Asset Management sold 21 Opus Genetics shares in Q3 2014, an estimated $9K.
  • Fisher Asset Management first reported a position in Opus Genetics in Q2 2014 and held it in 1 quarter.
  • Fisher Asset Management's Opus Genetics position peaked at $9K in Q2 2014.
  • 31 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2014.

Based on Fisher Asset Management's 13F filing for Q3 2014, filed 20 Oct 2014.